Litcius/Paper detail

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Barliz Waissengrin, Abed Agbarya, Esraa Safadi, Hagit Padova, Ido Wolf

2021The Lancet Oncology190 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)MedicineCancerImmune systemTerm (time)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakImmunologyVirologyCancer researchInternal medicineDiseaseInfectious disease (medical specialty)OutbreakQuantum mechanicsPhysicsCOVID-19 and healthcare impactsCancer Immunotherapy and BiomarkersCOVID-19 Clinical Research Studies
Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors | Litcius